ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000076

Dopamine-receptor stimulation : biobehavioral and biochemical consequences

Identifieur interne : 000076 ( PascalFrancis/Curation ); précédent : 000075; suivant : 000077

Dopamine-receptor stimulation : biobehavioral and biochemical consequences

Auteurs : Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada]

Source :

Trends in neurosciences : (Regular edition) [ 0166-2236 ] ; 2000.

RBID : Pascal:01-0111009

Descripteurs français

Pascal (Inist)
- Article synthèse, Parkinsonisme, Récepteur dopaminergique, Dyskinésie, Lévodopa, Expression génique, Transmission gabaergique, Transmission glutamatergique, Noyau gris central, Parkinson maladie, Singe.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- Basal ganglion, Dopamine receptor, Dyskinesia, Gabaergic transmission, Gene expression, Glutamatergic transmission, Levodopa, Monkey, Parkinson disease, Parkinsonism, Review.

Abstract

The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that L-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.

A01	`01`	`1`		`@0 0166-2236`
A03		`1`		`@0 Trends neurosci. : (Regul. ed.)`
A05				`@2 23`
A06				`@2 10 @3 SUP`
A08	`01`	`1`	`ENG`	`@1 Dopamine-receptor stimulation : biobehavioral and biochemical consequences`
A11	`01`	`1`		`@1 CALON (Frédéric)`
A11	`02`	`1`		`@1 ABDALLAH HADJ TAHAR`
A11	`03`	`1`		`@1 BLANCHET (Pierre J.)`
A11	`04`	`1`		`@1 MORISSETTE (Marc)`
A11	`05`	`1`		`@1 GRONDIN (Richard)`
A11	`06`	`1`		`@1 GOULET (Martin)`
A11	`07`	`1`		`@1 DOUCET (Jean-Pierre)`
A11	`08`	`1`		`@1 ROBERTSON (George S.)`
A11	`09`	`1`		`@1 NESTLER (Eric)`
A11	`10`	`1`		`@1 DI PAOLO (Thérèse)`
A11	`11`	`1`		`@1 BEDARD (Paul J.)`
A14	`01`			`@1 Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL) @2 Québec, G1V 4G2 @3 CAN @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 10 aut.`
A14	`02`			`@1 Faculty of Pharmacy, Laval University @2 Québec, G1K 7P4 @3 CAN @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 10 aut.`
A14	`03`			`@1 Neuroscience Research Unit, Laval University Medical Center (CHUL) @2 Québec, G1V 4G2 @3 CAN @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 11 aut.`
A14	`04`			`@1 Dept of Medicine, Faculty of Medicine, Laval University @2 Québec, G1K 7P4 @3 CAN @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 11 aut.`
A14	`05`			`@1 Dept of Pharmacology, Faculty of Medicine, University of Ottawa @2 Ottawa, Ontario @3 CAN @Z 7 aut. @Z 8 aut.`
A14	`06`			`@1 Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center @2 New Haven, CT 06508 @3 USA @Z 9 aut.`
A20				`@2 S92-S100`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18018B @5 354000092959410120`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 86 ref.`
A47	`01`	`1`		`@0 01-0111009`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Trends in neurosciences : (Regular edition)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that L-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Article synthèse @5 01`
C03	`01`	`X`	`ENG`	`@0 Review @5 01`
C03	`01`	`X`	`SPA`	`@0 Artículo síntesis @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 03`
C03	`03`	`X`	`ENG`	`@0 Dopamine receptor @5 03`
C03	`03`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 03`
C03	`04`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`04`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`04`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @5 05`
C03	`05`	`X`	`ENG`	`@0 Levodopa @5 05`
C03	`05`	`X`	`SPA`	`@0 Levodopa @5 05`
C03	`06`	`X`	`FRE`	`@0 Expression génique @5 06`
C03	`06`	`X`	`ENG`	`@0 Gene expression @5 06`
C03	`06`	`X`	`SPA`	`@0 Expresión genética @5 06`
C03	`07`	`X`	`FRE`	`@0 Transmission gabaergique @5 07`
C03	`07`	`X`	`ENG`	`@0 Gabaergic transmission @5 07`
C03	`07`	`X`	`SPA`	`@0 Transmisión gabaérgica @5 07`
C03	`08`	`X`	`FRE`	`@0 Transmission glutamatergique @5 08`
C03	`08`	`X`	`ENG`	`@0 Glutamatergic transmission @5 08`
C03	`08`	`X`	`SPA`	`@0 Transmision glutamatérgica @5 08`
C03	`09`	`X`	`FRE`	`@0 Noyau gris central @5 10`
C03	`09`	`X`	`ENG`	`@0 Basal ganglion @5 10`
C03	`09`	`X`	`SPA`	`@0 Núcleo basal @5 10`
C03	`10`	`X`	`FRE`	`@0 Parkinson maladie @5 12`
C03	`10`	`X`	`ENG`	`@0 Parkinson disease @5 12`
C03	`10`	`X`	`SPA`	`@0 Parkinson enfermedad @5 12`
C03	`11`	`X`	`FRE`	`@0 Singe @5 54`
C03	`11`	`X`	`ENG`	`@0 Monkey @5 54`
C03	`11`	`X`	`SPA`	`@0 Mono @5 54`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 45`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 45`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 45`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 46`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 46`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 46`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 47`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 47`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 47`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 48`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 48`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 48`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 49`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 49`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 49`
C07	`06`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`06`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`06`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`07`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`08`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 071`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C47

Links to Exploration step

Pascal:01-0111009

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine-receptor stimulation : biobehavioral and biochemical consequences</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Grondin, Richard" sort="Grondin, Richard" uniqKey="Grondin R" first="Richard" last="Grondin">Richard Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Goulet, Martin" sort="Goulet, Martin" uniqKey="Goulet M" first="Martin" last="Goulet">Martin Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Doucet, Jean Pierre" sort="Doucet, Jean Pierre" uniqKey="Doucet J" first="Jean-Pierre" last="Doucet">Jean-Pierre Doucet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Dept of Pharmacology, Faculty of Medicine, University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S." last="Robertson">George S. Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Dept of Pharmacology, Faculty of Medicine, University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Nestler, Eric" sort="Nestler, Eric" uniqKey="Nestler E" first="Eric" last="Nestler">Eric Nestler</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center</s1>
<s2>New Haven, CT 06508</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0111009</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0111009 INIST</idno>
<idno type="RBID">Pascal:01-0111009</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000076</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine-receptor stimulation : biobehavioral and biochemical consequences</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Grondin, Richard" sort="Grondin, Richard" uniqKey="Grondin R" first="Richard" last="Grondin">Richard Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Goulet, Martin" sort="Goulet, Martin" uniqKey="Goulet M" first="Martin" last="Goulet">Martin Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Doucet, Jean Pierre" sort="Doucet, Jean Pierre" uniqKey="Doucet J" first="Jean-Pierre" last="Doucet">Jean-Pierre Doucet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Dept of Pharmacology, Faculty of Medicine, University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S." last="Robertson">George S. Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Dept of Pharmacology, Faculty of Medicine, University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Nestler, Eric" sort="Nestler, Eric" uniqKey="Nestler E" first="Eric" last="Nestler">Eric Nestler</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center</s1>
<s2>New Haven, CT 06508</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Trends in neurosciences : (Regular edition)</title>
<title level="j" type="abbreviated">Trends neurosci. : (Regul. ed.)</title>
<idno type="ISSN">0166-2236</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Trends in neurosciences : (Regular edition)</title>
<title level="j" type="abbreviated">Trends neurosci. : (Regul. ed.)</title>
<idno type="ISSN">0166-2236</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Basal ganglion</term>
<term>Dopamine receptor</term>
<term>Dyskinesia</term>
<term>Gabaergic transmission</term>
<term>Gene expression</term>
<term>Glutamatergic transmission</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Review</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Article synthèse</term>
<term>Parkinsonisme</term>
<term>Récepteur dopaminergique</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Expression génique</term>
<term>Transmission gabaergique</term>
<term>Transmission glutamatergique</term>
<term>Noyau gris central</term>
<term>Parkinson maladie</term>
<term>Singe</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that L-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-2236</s0>
</fA01>
<fA03 i2="1"><s0>Trends neurosci. : (Regul. ed.)</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>10</s2>
<s3>SUP</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Dopamine-receptor stimulation : biobehavioral and biochemical consequences</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CALON (Frédéric)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ABDALLAH HADJ TAHAR</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BLANCHET (Pierre J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MORISSETTE (Marc)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GRONDIN (Richard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GOULET (Martin)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DOUCET (Jean-Pierre)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROBERTSON (George S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>NESTLER (Eric)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>DI PAOLO (Thérèse)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BEDARD (Paul J.)</s1>
</fA11>
<fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Dept of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Dept of Pharmacology, Faculty of Medicine, University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center</s1>
<s2>New Haven, CT 06508</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s2>S92-S100</s2>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18018B</s2>
<s5>354000092959410120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>86 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0111009</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Trends in neurosciences : (Regular edition)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that L-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Review</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Expression génique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Gene expression</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Expresión genética</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Transmission gabaergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Gabaergic transmission</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Transmisión gabaérgica</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Transmission glutamatergique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Glutamatergic transmission</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Transmision glutamatérgica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Singe</s0>
<s5>54</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Monkey</s0>
<s5>54</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Mono</s0>
<s5>54</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>49</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>49</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>49</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>071</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000076 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000076 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0111009
   |texte=   Dopamine-receptor stimulation : biobehavioral and biochemical consequences
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Dopamine-receptor stimulation : biobehavioral and biochemical consequences

Dopamine-receptor stimulation : biobehavioral and biochemical consequences

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri